SCHEMBL21472486

SCHEMBL21472486

CC(C)CCNc1c(N)c(=O)c1=S

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.40
GRIN2D O15399 5/20 0.36
GRIN3B O60391 5/20 0.36
GRIN1 Q05586 5/20 0.36
GRIN2A Q12879 5/20 0.36
GRIN2B Q13224 5/20 0.36
GRIN2C Q14957 5/20 0.36
GRIN3A Q8TCU5 5/20 0.36
POLB P06746 1/20 0.35
TSHR P16473 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSD17B10 Q99714 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2C8 P10632 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21842714 0.88 GRIN2D (0.38) ALDH1A1KDM4EMEN1GAAKMT2A
SCHEMBL24806467 0.86 GRIN2D (0.34) ALDH1A1KDM4EMEN1GAAKMT2A
SCHEMBL24937755 0.86 ALDH1A1 (0.40) ALDH1A1KDM4EMEN1GAAKMT2A
SCHEMBL21472286 0.83 GRIN2D (0.52) ALDH1A1KDM4EMEN1GAAKMT2A
SCHEMBL24806196 0.83 KDM4E (0.36) ALDH1A1KDM4EMEN1GAAKMT2A
SCHEMBL23267796 0.79 GRIN2D (0.42) ALDH1A1KDM4EMEN1GAAKMT2A
SCHEMBL24806172 0.77 KDM4E (0.36) ALDH1A1KDM4EMEN1GAAKMT2A
SCHEMBL22943394 0.76 GRIN2D (0.42) ALDH1A1KDM4EMEN1GAAKMT2A
SCHEMBL24807527 0.76 CYP1A2 (0.36) ALDH1A1KDM4EMEN1GAAKMT2A
SCHEMBL21472555 0.75 GRIN2D (0.36) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230027864-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS MODERNATX, INC. 2023-01-26 US disclosed
US-20190314291-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS MODERNATX, INC. 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027864-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS LCP2, CD14, MYD88 ALDH1A1 4722/4885KDM4E 4100/4885MEN1 3810/4885
US-20190314291-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS LCP2, CD14, MYD88 ALDH1A1 4722/4885KDM4E 4100/4885MEN1 3810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.